Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 72, Issue 2, 2006, Pages 148-154

  Suzuki, Kazuko ^a,b   Yanagawa, Tatsuo ^a   Shibasaki, Toshiaki ^b   Kaniwa, Nahoko ^c   Hasegawa, Ryuichi ^c   Tohkin, Masahiro ^c  

^a Nerima General Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Cytochrome P450; Genetic polymorphism; Pharmacokinetics; Sulfonylurea; Type 2 diabetes

Indexed keywords

CYTOCHROME P450 2C9; GLIMEPIRIDE; HEMOGLOBIN A1C;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; HYDROXYLATION; JAPAN; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; SULFONYLUREA COMPOUNDS;

EID: 33646122444     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.09.019     Document Type: Article

References (29)

1. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care 15 6 (1992) 737-754
2. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann. Int. Med. 128 3 (1998) 165-175
3. Holstein A., and Egberts E.H. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 111 7 (2003) 405-414
4. Schneider J. An overview of the safety and tolerance of glimepiride. Horm. Metab. Res. 28 9 (1996) 413-418
5. Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin. Ther. 25 3 (2003) 799-816
6. 1c and body weight in type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res. Clin. Pract. 61 1 (2003) 13-19
7. Campbell R.K. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 32 10 (1998) 1044-1052
8. Rosenstock J., Samols E., Muchmore D.B., and Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19 11 (1996) 1194-1199
9. Muller G., Hartz D., Punter J., Okonomopulos R., and Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim. Biophys. Acta 1191 2 (1994) 267-277
10. Kabadi M.U., and Kabadi U.M. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin. Ther. 26 1 (2004) 63-69
11. Badian M., Korn A., Lehr K.H., Malerczyk V., and Waldhausl W. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabol. Drug Interact. 11 4 (1994) 331-339
12. Niemi M., Cascorbi I., Timm R., Kroemer H.K., Neuvonen P.J., and Kivisto K.T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 72 3 (2002) 326-332
13. Yamazaki H., and Tabata S. Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats. Arzneimittelforschung 43 12 (1993) 1317-1321
14. Rosenkranz B., Profozic V., Metelko Z., Mrzljak V., Lange C., and Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39 12 (1996) 1617-1624
15. Xie H.G., Prasad H.C., Kim R.B., and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54 10 (2002) 1257-1270
16. Lee C.R., Goldstein J.A., and Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12 3 (2002) 251-263
17. Takanashi K., Tainaka H., Kobayashi K., Yasumori T., Hosakawa M., and Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10 2 (2000) 95-104
18. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 4 (1996) 341-349
19. Inoue K., Yamazaki H., Imiya K., Akasaka S., Guengerich F.P., and Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7 2 (1997) 103-113
20. Kirchheiner J., Bauer S., Meineke I., Rohde W., Prang V., Meisel C., et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12 2 (2002) 101-109
21. Shon J.H., Yoon Y.R., Kim K.A., Lim Y.C., Lee K.J., Park J.Y., et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12 2 (2002) 111-119
22. Miners J. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response. Pharmacogenetics 12 2 (2002) 91-92
23. Lee C.R., Pieper J.A., Hinderliter A.L., Blaisdell J.A., and Goldstein J.A. Evaluation of cytochrome P450 2C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin. Pharmacol. Ther. 72 5 (2002) 562-571
24. Salem I.I., Idrees J., and Al Tamimi J.I. Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 799 1 (2004) 103-109
25. Takahashi H., Wilkinson G.R., Caraco Y., Muszkat M., Kim R.B., Kashima T., et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73 3 (2003) 253-263
26. Hiratsuka M., Agatsuma Y., and Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol. Genet. Metab. 68 3 (1999) 357-362
27. Kimura M., Ieiri I., Mamiya K., Urae A., and Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit. 20 3 (1998) 243-247
28. Takahashi H., and Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40 8 (2001) 587-603
29. Charpentier G., Vaur L., Halimi S., Fleury F., Derobert E., Grimaldi A., et al. Predictors of response to glimepiride in patients with type 2 diabetes mellitus. Diabetes Metab. 27 5 Pt 1 (2001) 563-571